Previous studies have suggested an important role of ERs (oestrogen receptors) in the pathogenesis of leukaemias. However, there is no information so far about the epigenetic characteristics of ERα isoforms and ERβ in leukaemias. In the present study, the mRNA expression and promoter CpG methylation of ERα isoforms (i.e. ERα-A, -B and -C) and ERβ in leukaemia cell lines were evaluated using RT-PCR (reverse transcription-PCR) and MSP (methylation-specific PCR) respectively. The methylation of ERs was further analysed in acute leukaemia patients by MSP and direct DNA sequencing. Although all ERα isoforms and ERβ were methylated in all leukaemia cell lines, except for ERα-C, which was unmethylated in HL-60 and K562 cell lines, only the expression of ERα-A was deficient in all cell lines and its expression could be reactivated by DNA demethylation reagents. With regard to the methylation characteristics in acute leukaemia patients, only ERα-A was inactivated and specifically methylated (95%; 38/40) in almost all patients and unmethylated in all healthy controls, whereas ERα-B, -C and ERβ were methylated in both patients and healthy controls. This result suggested that the methylated status of ERα-A might serve as an epigenetic biomarker of leukaemias. The present study is the first report that demonstrates selective inactivation of ERα isoforms through the promoter CpG methylation pathway in leukaemias.
INTRODUCTION
Among various epigenetic events associated with human cancers, it is well documented that the aberrant promoter methylation plays a significant role in the epigenetic tumorigenesis of various human cancers [1] . To date, aberrant methylation of multiple gene promoters has been described in various leukaemias, such as ALL (acute lymphocytic leukaemia) and AML (acute myeloid leukaemia), and the results suggested a potential role of promoter methylation profiles in the diagnosis, prognosis or treatment prediction of acute leukaemias [2] [3] [4] .
ERs (oestrogen receptors) are members of the nuclear steroidthyroid hormone receptor superfamily. Two forms of ER, i.e. ERα and ERβ, have been identified [5] . Aberrant methylation of the ER promoter and associated epigenetic silencing of ER expression have been reported in various human cancers, such as breast cancer and colorectal carcinomas [5, 6] . In human acute leukaemias, it has been reported that the aberrant methylation of ERα promoter was correlated with its epigenetic silencing, and can serve as epigenetic biomarkers in the diagnosis, prognosis and treatment prediction of leukaemias [4] [5] [6] . Three promoters, i.e. A, B and C, have been identified for the human ERα gene [7] . These promoters regulate the synthesis of specific transcripts corresponding to ERα-A, -B and -C isoforms [7] . Previous studies have shown that the expression of the above ERα isoforms could be regulated by promoter CpG methylation in human cancers, such as endometrial cancer [8] . We were interested in determining whether there is epigenetic regulation of ERα isoform expression by promoter CpG islands in human leukaemia. Moreover, studies have suggested a potential role of ERβ in leukomogenesis because the inactivation of ERβ in mice leads to a leukaemia-like syndrome [9] . In the present study, analysis was performed on the expression profile of ERα isoforms (i.e. ERα-A, -B and -C) and ERβ and their methylation status in acute leukaemias. This question is critical in understanding the complexity of ER gene expression and regulation in leukaemia cells. β-Actin-r TCGGTGAGGATCTTCATGAG *In the customized name of each primer, the f and r refer to the forward and reverse primers of a certain set of primer respectively; the M and U refer to primers annealed to methylated and unmethylated genomic DNA respectively W, wild-type (used as a positive control).
MATERIALS AND METHODS

Cell culture and treatment with demethylation reagent
Jurkat, HL-60, K562, U937, THP-1 and MOLT-4 cells were maintained in RPMI 1640 medium containing 10% (v/v) fetal bovine serum. The cells were treated with a freshly prepared solution of 5-aza-dC (5-aza-2 -deoxycytidine; Sigma, St. Louis, MO, U.S.A.) according to published protocols [8, 10] . On day 1, a final concentration of 2 mg/ml 5-aza-dC in PBS was added to the flask. On the following day, the medium was changed. On days 3 and 5, the cells were treated twice more as on day 1. On day 6, the cells were harvested.
Clinical blood samples of acute leukaemia patients
The present study was approved by local institutional review boards or ethics committees. The whole blood samples were collected from 40 cases of acute leukaemia patients having no record of any previous treatments in the Southwest Hospital (Chongqing, China) in 2006-2007. Ten samples of whole blood were collected from healthy volunteers. The histopathological types of leukaemia patients were identified by a pathologist having no connection with the present study. All patients were ethnic Chinese, and written informed consent had been obtained from all of them or their family members.
RNA isolation and RT-PCR (reverse transcription-PCR)
Cells were washed and lysed with guanidine isothiocyanate solution. Total RNA was extracted using an RNA Extraction kit for culture cells (TaKaRa, Dialian, China) by following the manufacturer's instructions. Three forward primers, i.e. RT-A, RT-B and RT-C, were respectively combined with a common reverse primer, i.e. RT-r, to specifically amplify transcript isoforms from promoters A, B and C respectively. A set of primers 
(RT-Common-f and RT-Common-r) was used to amplify transcripts common to these promoters. A set of primers (RT-ERβ-f and RT-ERβ-r) was used to specifically amplify transcripts of ERβ. Primers for β-actin were chosen specifically to amplify one intron in the β-actin gene. In the presence of contaminating genomic DNA, additional larger bands would be amplified; the lack of amplification of the larger band was used as a control to rule out contamination with any genomic DNA. The sequences and PCR cycling conditions were listed in Table 1 . 
DNA extraction and sodium bisulfite treatment
MSP (methylation-specific PCR) and DNA sequencing
The bisulfite-converted genomic DNA was amplified by MSP using the primer sets listed in Table 1 Table 1 , in which one primer set (U) will anneal to unmethylated DNA, and a second primer set (M) will anneal to methylated DNA.
RESULTS
Expression profile and methylation status of ER in leukaemia cell lines
MSP and RT-PCR were performed to analyse the methylation status and mRNA expression respectively of three ERα isoforms (i.e. ERα-A, -B and -C) and ERβ on the leukaemia cell lines with or without 5-aza-dC demethylation treatment (Table 2 and Figures 1 and 2 ).
Without treatment with 5-aza-dC, the promoters of ERα-A, -B and -C and ERβ were fully methylated or semi-methylated in all leukaemia cell lines, including Jurkat, HL-60, K562, U937, THP-1 and MOLT-4, except for ERα-C, which was fully methylated in HL-60 and K562. However, only the expression of ERα-A was deficient in the above six leukaemia cell lines. With the DNA demethylation treatment with 5-aza-dC, the expression of ERα-A was restored in all cell lines, and there were no changes in the expression of ERα-B, and -C and ERβ. 
Expression profile and methylation status of ERs in clinical patients with acute leukaemia
To further evaluate the methylation status and expression activity of ER promoter in leukaemia, RT-PCR and MSP were performed to analyse the promoter expression and CpG methylation of ERα isoforms (i.e. ERα-A, -B and -C) and ERβ in 40 cases of leukaemia patients that consisted of 12 cases of ALL, 21 cases of AML and seven cases of an unknown type of acute leukaemia (Table 3 and Figure 3 ). Compared with full unmethylation in all healthy controls (100%; 10/10), ERα-A promoter was semi-methylated and its expression was inactivated in almost all of the leukaemia patients (95%; 38/40), including 92% (11/12) in ALL, 95% (20/21) in AML and 100% (7/7) in an unknown type of acute leukaemia. Compared with full methylation of ERα-A promoter, the other two isoforms of ERα, i.e. ERα-B and -C, showed full and semi-methylation in healthy controls respectively. There were no apparent methylation patterns of both ERα-B and -C in leukaemia patients except when both of them were methylated. ERβ was found to be fully methylated in all patients (100%; 40/40) and healthy controls.
DISCUSSION
The ERs are members of a closely related subgroup of nuclear receptors that includes the androgen, mineralcorticoid and glucocorticoid receptors. Previous studies have revealed that the expression of ERs including both ERα and ERβ could be controlled by both genetic and epigenetic mechanisms in various human cancers [5, 7] , and the promoter CpG methylation of ERα plays an important role in the leukomogenesis and could serve as an epigenetic biomarker of leukaemias [11, 12] . promoters have been identified to control the expression of ERα isoforms including ERα-A, -B and -C [13] . Previous studies have indicated that there is a selective use of ERα isoforms in various human cancers [7, 8, 14] , and the promoter CpG methylation plays an important role in the control of its isoform expression [8] . For example, one study indicated that only ERα-C was specifically methylated in an endometrial cell line and tumour tissues, and the expression of ERα-C could be reactivated by demethylation of its promoter CpG dinucleotides [8] . However, it is still not clear whether there is a selective use of ERα isoforms that is controlled by promoter CpG methylation in human leukaemia. Moreover, leukaemia-like diseases induced by inactivation of ERβ in the mouse model also suggested a role of ERβ in leukomogenesis [9] . In the present study, we investigated the expression of three isoforms of ERα (i.e. ERα-A, -B and -C) and ERβ in leukaemia cell lines and patients with acute leukaemia. We found that only the transcript from the proximal promoter, i.e. ERα-A, was inactivated in almost all of the leukaemia cell line (95%; 38/40) in patients with acute leukaemia, whereas both transcripts of ERα-B and ERα-C were present (Table 2) . We also investigated mechanisms of inactivation of the ERα-A gene through the analysis of promoter CpG methylation using MSP. Although the three isoforms of ERα (i.e. ERα-A, -B and -C) and ERβ were methylated (i.e. semi-methylated or fully methylated) in all of the leukaemia cell lines, except for ERα-C, which was unmethylated in HL-60 and K562 cell lines, only ERα-A was fully unmethylated in healthy controls (Table 3 ). The expression of ERα-A could be reactivated by DNA demethylation with 5-aza-dC. The results suggested that the selective deficient expression of ERα-A was controlled by its promoter CpG methylation.
To further understand the methylation characteristics of ER gene families in leukaemias, we also investigated the expression activity and methylation status of various ERs in whole blood from clinical leukaemia patients (Table 3) . Compared with ERα-B, -C and ERβ, which were methylated (i.e. semi-methylated or fully methylated) in both leukaemia patients and healthy controls, only ERα-A was inactivated in expression and specifically and highly methylated (95%; 38/40) in almost all leukaemia patients and was fully unmethylated in all healthy controls. This result suggested that the methylated status of ERα-A might serve as an epigenetic biomarker of leukaemias. Combined with the epigenetic reactivation of ERα-A in leukaemia cell lines, we concluded that the ERα-A plays an important role in the leukomogenesis.
In conclusion, this is the first report on extensive studies of ERα isoforms (i.e. ERα-A, -B and -C) and ERβ in leukaemia.
Inactivation of the ERα-A gene through promoter CpG methylation may be important in the pathogenesis of leukaemia.
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